Citation: | ZHOU Ping, LI Li, WU Lulu, GU Chenhao, TIAN Huimin, REN Xiaoming, ZHANG Haijun, WU Jiaquan. Determination of osimertinib mesylate by HPLC[J]. Journal of China Pharmaceutical University, 2017, 48(3): 322-327. DOI: 10.11665/j.issn.1000-5048.20170312 |
[1] |
Cross DA,Ashton SE,Ghiorghiu S,et al.AZD9291,an irreversible EGFR TKI,overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J].Cancer Discov,2014,4(9):1046-1061.
|
[2] |
Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-792.
|
[3] |
Yang X,Liangan C.Advances in primary resistance to EGFR-TKI in patients with non-small cell lung cancer[J].Acad J Chin PLA Med Sch(解放军医学院学报),2013,34(4):418-420.
|
[4] |
Jiang T,Zhou C.Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer[J].Trans Lung Cancer Res,2014,3(6):370-372.
|
[5] |
U.S.Food and Drug Administration.FDA approves new pill to treat certain patients with non-small cell lung cancer[EB/OL].https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm.
|
[6] |
Liu H,Lyu Y,Li Y,et al.A novel and efficient synthesis of anti-cancer agent,mereletinib[J].J Chem Res,2015,39(6):318-320.
|
[7] |
Butterworth S,Finlay MR,Ward RA,et al.Preparation of 2-(2,4,5-substituted-anilino)pyrimidine derivatives as EGFR modulators useful for treating cancer:WO,2013/14448[P].2012-07-25[2013-01-31] .
|
[8] |
Rood JJ,van Bussel MT,Schellens JH,et al.Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib(AZD9291)in human plasma[J].J Chromatogr B,2016,1031:80-85.
|